Klion-D 100 is commonly used to help with the local management of mixed vaginal infections in adult women. This combination is generally applied in addressing conditions involving protozoal infections, such as Urogenital Trichomoniasis, and infections caused by susceptible fungal pathogens, like Candida species.

This approach is relevant in scenarios marked by heightened symptoms resulting from the concurrent presence of both pathogens. The medication helps address symptom clusters that may become intense or disruptive, including severe vaginal itching, burning, and abnormal discharge that interfere with daily comfort. This localized approach contributes to improved comfort during symptomatic periods. The formulation may assist with maintaining functional stability in patients experiencing recurrent symptomatic episodes and contributes to easing the risk of secondary fungal overgrowth.

Quick Fact: Relief for Dual Discomfort
This combination is relevant for easing itching and burning sensations commonly associated with both yeast and Trichomonas infections.

Population Eligibility and Restrictions

Klion-D 100 is approved for use primarily in adult women for the local management of mixed vaginal infections. Regulatory authorities strictly define patient eligibility, with specific groups being absolutely prohibited from using the medicine (contraindicated) and others requiring use only under restricted conditions.

---

Absolute Contraindications

Use of Klion-D 100 is strictly prohibited in the following populations:

• Patients with documented hypersensitivity or allergy to Metronidazole, Miconazole, or related derivatives.
• Female patients in the first trimester of pregnancy.
• Individuals with a history of blood dyscrasias, acute porphyria, or active organic disease of the central nervous system.

---

Restricted and Conditional Use

• Pregnancy (after first trimester): May be used only if considered essential by a physician and under careful medical supervision.
• Organ Function: Use requires caution in patients with severe liver function disorders or those predisposed to seizures.
• Age Limits: The safety and efficacy have not been established in children, and use is not recommended before the onset of menstruation. Breastfeeding patients should also use this product with caution or temporarily discontinue feeding.

Interactions with Other Medicines and Products

The Klion-D 100 interaction profile is governed by restrictions related to its active components, Metronidazole and Miconazole Nitrate. Co-administration with Alcohol (Ethanol) or products containing Propylene Glycol is strictly contraindicated due to the risk of a severe disulfiram-like reaction; avoidance must be maintained for at least 3 days following the final dose. Similarly, Disulfiram is contraindicated and must not have been taken within the preceding 14 days of starting therapy, as this combination has been associated with psychotic reactions.

A primary concern is the pharmacokinetic interaction with Oral Coumarin Anticoagulants (e.g., Warfarin). Both Metronidazole and Miconazole potentiate the anticoagulant effect, leading to a documented prolongation of Prothrombin Time/INR. Regulatory information also documents that co-administration can affect the systemic exposure of several drugs: the plasma concentrations of Lithium and Busulfan are increased, raising toxicity risk, while Phenobarbital is documented to decrease the blood levels of Metronidazole. Caution is additionally noted for patients with severe liver disease due to the potential for slower clearance of the Metronidazole component. Finally, the excipients in the vaginal formulation may compromise the structural integrity and reliability of latex or rubber barrier contraceptives such as condoms and diaphragms.

How Klion-D 100 Works: The Dual-Mechanism Assault

Klion-D 100 exerts its localized effect through two distinct and complementary mechanisms, ensuring a mechanism of action that addresses distinct microbial classes.

---

Destruction via Pathogen DNA Disruption (Metronidazole)

This domain covers the action against susceptible protozoa and anaerobic bacteria. The drug is chemically activated by the low-oxygen environment within the pathogen's cells, utilizing microbial electron transport proteins to generate cytotoxic radicals. These radicals bind irreversibly to the pathogen's DNA and nucleic acids, causing strand breakage. This molecular cascade leads to the killing of the microbial cell (protozoacidal and bactericidal effect), contributing to the destruction of the sensitive pathogen population.

---

Fungal Cell Membrane Structural Failure (Miconazole)

The antifungal component targets the synthesis of ergosterol in fungal organisms, such as Candida species. Miconazole acts as an inhibitor of the fungal enzyme CYP51, which is crucial for manufacturing this vital membrane component. The resulting depletion of ergosterol causes structural failure and increased permeability in the fungal cell wall, leading to cell lysis and destruction (fungicidal effect), contributing to the destruction of the sensitive fungal population.

---

Complementary Pathogen Destruction

The combination provides mechanisms that are additive in their spectrum of microbial activity, where each agent targets a different biological pathway and class of organism. This dual mechanism ensures that both bacterial/protozoal and fungal threats are addressed simultaneously, resulting in the destruction of diverse microbial populations at the site of action.

Official Administration Guidelines

Klion-D 100 is a fixed-dose combination product containing 100 mg of Metronidazole and 100 mg of Miconazole Nitrate in a single unit, designed exclusively for local administration. The usage pattern is defined by adherence to the specified route, dosage, frequency, and duration as established in official product labeling. The medicine is not to be swallowed under any circumstances, as it is formulated solely for its local effect.

---

Core Usage Protocol

The standard adult local dose is one (1) vaginal tablet administered once daily (q.d.). This single unit dose is typically maintained throughout the course of therapy. Administration is required at night or just before going to bed (qHS) to ensure prolonged local contact with the active ingredients.

The standard duration of treatment is a 10-day course. This fixed duration applies to both the local management of Candida-related infection and the local component of combined treatment for Trichomonas-related infection. For the management of Urogenital Trichomoniasis, the protocol requires concurrent oral treatment of the sexual partner with metronidazole to minimize recurrence risk.

---

Procedural Requirements and Constraints

Instruction Category	Procedural Rule
Route of Administration	Strictly intravaginal use only.
Preparation	The tablet must be slightly moistened with water prior to deep insertion.
Timing	Administered once daily at night (before bed).
Age Restriction	Not for use in children under 12 years; standard adult dose applies for older adults (over 65 years).

Proper administration involves inserting the tablet deeply while in a lying position. Product information notes that use is generally restricted during menstruation.

Evidence for Use in Mixed Vaginal Infections

Research on the Metronidazole/Miconazole vaginal combination has explored its use in mixed vaginal infections through Randomized Controlled Trials (RCTs). These studies monitored microbiological clearance of multiple pathogens and clinical symptom resolution (e.g., changes in discharge, itching, and burning) over short-term periods. However, the precise definition of "mixed infection" has varied across studies, and long-term effects are not fully established due to limited follow-up durations.

---

Evidence for Use in Single Infections: BV, VVC, and Trichomoniasis

Bacterial Vaginosis (BV)

RCTs explored the combination's use alongside oral standard treatments, monitoring microbiological and clinical outcomes. Research has also explored its use in preventative regimens, though data are more extensive for short-term outcomes.

Vulvovaginal Candidiasis (VVC)

Research examined the combination through RCTs alongside antifungal monotherapies, measuring microbiological clearance and symptom resolution. The volume of dedicated evidence for VVC alone remains moderate.

Trichomoniasis

Trials studied the vaginal combination alongside the systemic oral standard-of-care. Comparative evidence is lacking from large-scale studies, which reflects the general emphasis on systemic treatment for this infection in clinical guidelines.

---

Long-Term Studies and Durability of Follow-up

Extended studies monitored recurrence rates, particularly for Bacterial Vaginosis. However, long-term effects are not fully established for a standard, single course of therapy, as much of the evidence was observed in periodic regimens for patients with a history of recurrence.

---

Evidence in Study Populations and Subgroups

Clinical research was observed in a relatively specific group: generally adult women between 18 and 45 years old. Data for certain groups remain insufficient, particularly for children, older adults, or women who are pregnant, as these groups were generally excluded from the main clinical research trials.

---

Key Limitations and Areas of Research Uncertainty

The research base highlights several uncertainties. Evidence quality varies across studies due to modest sample sizes and limited follow-up durations. Findings were mixed or inconsistent across studies, particularly when comparing the topical combination to a systemic (oral) standard-of-care, where the difference in administration route presents a challenge.

Key Studies & References

1. Randomized, single-blinded comparison of efficacy, safety and tolerability of metronidazole 750mg-miconazole 200mg vaginal suppositories and metronidazole 500mg-nystatin 100000IU vaginal suppositories in the treatment of vaginitis
2. Comparative Effectiveness of Treatments for Bacterial Vaginosis: A Network Meta-Analysis

Common questions about Klion-D 100 (FAQ)

---

Q: What is the difference between Klion-D 100 and other Metronidazole-only treatments?

A: Klion-D 100 is a dual-component product that contains both Metronidazole and Miconazole Nitrate. This combination provides a broad spectrum of activity that targets both susceptible protozoa and anaerobic bacteria (Metronidazole), as well as fungi (Miconazole). In contrast, Metronidazole-only treatments typically target only the protozoal and bacterial spectrum of infections.

Q: How long does it usually take to notice an improvement in symptoms with Klion-D 100?

A: Studies and official documents confirm that clinical trials have monitored the short-term resolution of symptoms such as discharge, burning, and itching. However, regulatory documents generally do not define a specific number of days within which an individual must notice a specific level of improvement.

Q: Are there specific food items or supplements that interact with Klion-D 100?

A: Official regulatory documents list specific interactions with certain medicines and products, most notably Alcohol and Propylene Glycol. These documents do not typically list specific food items or common dietary supplements as being contraindicated or causing known interactions with the vaginal tablet formulation.

Q: Is it safe to use tampons or other feminine hygiene products while on this treatment?

A: Regulatory documents note that the excipients in the vaginal tablet formulation may compromise the structural integrity of latex or rubber barrier contraceptives like condoms. Official product information does not include an explicit statement regarding the use of non-barrier feminine hygiene products, such as tampons.

Q: Does Klion-D 100 cause any changes in mood or sleep patterns?

A: Official safety information lists systemic effects like headache and dizziness under Nervous System Disorders, which can sometimes occur due to the small amount of systemic absorption. However, changes in mood or sleep patterns are generally not listed as common or uncommon adverse reactions for the local formulation of this medicine.

Q: How quickly do the active components of Klion-D 100 absorb into the bloodstream?

A: Regulatory pharmacokinetic studies indicate that only a small amount of Metronidazole and Miconazole is absorbed systemically following vaginal administration. The local application is designed to concentrate the medicine at the infection site, resulting in low peak plasma concentrations compared to when the drugs are taken orally.

Q: Does Klion-D 100 have different effects on the body than oral Metronidazole?

A: Yes, the combination product Klion-D 100 is designed for local application in the vagina and features a dual-action against two different classes of pathogens. Oral Metronidazole is a single agent intended for systemic absorption to produce a generalized effect throughout the body.

Q: What are the signs of a serious side effect from Klion-D 100 that require immediate attention?

A: Serious but rare adverse reactions documented in regulatory information include severe hypersensitivity reactions and severe mucocutaneous reactions like Stevens-Johnson syndrome (SJS). Official information generally describes that signs of a severe allergic reaction, such as swelling of the face, tongue, or throat, or a severe, blistering, or peeling rash, are cause for medical consultation.

Q: What is the difference in formulation between Klion-D 100 and other vaginal pessaries?

A: Official regulatory documents detail that Klion-D 100 contains the active components Metronidazole and Miconazole Nitrate, along with a specific list of inactive excipients (fillers and binders). The choice of active ingredients and these excipients distinguishes its formulation from other general vaginal pessaries.

Q: How does the local application of Klion-D 100 minimize systemic side effects?

A: The primary goal of local administration is to concentrate the medication directly at the site of infection while facilitating low systemic absorption into the general bloodstream. This approach minimizes the body's overall exposure to the medication, reducing the potential for systemic side effects.

Q: What is the longest course of Klion-D 100 treatment usually prescribed?

A: The standard duration of treatment is a fixed 10-day course, as established in the regulatory guidelines. Official documents generally do not establish a fixed maximum course duration but state that the medicine should be used for the specified duration or as advised by a health professional.

Q: Is it common to have a white, creamy, or chalky discharge while using Klion-D 100?

A: The vaginal tablet contains excipients (fillers) that melt at body temperature after insertion. Official product information indicates that the residue of the melted or partially dissolved tablet may be discharged. While the discharge consistency is not explicitly described, the discharge of residue itself is a possibility due to the formulation.

Q: Are there any restrictions on sexual activity during the course of Klion-D 100 treatment?

A: Official documents note that the excipients in the vaginal tablet can affect the structural integrity of latex or rubber barrier contraceptives. Furthermore, the regulatory protocol for trichomoniasis requires the sexual partner to be treated concurrently. The official regulatory documents do not typically contain an explicit instruction regarding the prohibition of sexual activity itself during the course of treatment.

Q: Does Klion-D 100 affect the effectiveness of hormonal birth control pills?

A: Official regulatory documents state there is no known interaction documented between the vaginal tablet preparation and hormonal contraceptives, such as oral birth control pills. However, the medicine may compromise the structural integrity of latex or rubber barrier contraceptives.

Q: What happens if the recommended course of treatment with Klion-D 100 is not completed?

A: Regulatory guidelines stress the importance of completing the fixed 10-day course of treatment exactly as intended. While official documents do not explicitly list the specific outcomes of non-completion, regulatory guidelines suggest that discontinuing the full course prematurely may compromise treatment efficacy and increase the risk of recurrence.

Q: What happens if I forget to use a tablet one evening during the treatment course?

A: The regulatory guidance on managing a missed dose generally includes instruction to continue the treatment as scheduled the following evening and to avoid doubling the dose to compensate for the forgotten tablet.

Q: Does Klion-D 100 interfere with routine blood or urine laboratory tests?

A: Regulatory documentation notes that Metronidazole, one of the active ingredients, may interfere with certain laboratory methods. This potential interference has been observed when measuring certain liver enzymes or other blood markers, and may lead to spuriously low or misleading results.

Q: Is it normal for pieces of the tablet to be discharged the morning after use?

A: Due to the excipients (inactive components) used in the tablet formulation, it is described in official product information that residue of the melted or partially dissolved tablet may be discharged following use. This is a possibility related to the physical properties of the vaginal tablet.

Q: Are there special conditions under which the Klion-D 100 course can be repeated?

A: Regulatory guidelines do not establish a standard interval for repeat courses. They advise that if the infection recurs, the patient should be re-evaluated by a healthcare provider before any subsequent course is initiated, as repeated use may carry a risk of resistance.

Q: Does Klion-D 100 interact with common over-the-counter medications like Ibuprofen?

A: Regulatory documents list known interactions with certain prescription medications like Warfarin and Lithium. No documented interaction is generally listed for the vaginal preparation with common over-the-counter pain relievers such as Ibuprofen or Paracetamol.

Q: Is it true that Metronidazole can increase sensitivity to sunlight?

A: Regulatory information documents rare adverse reactions affecting the skin. While increased sensitivity to sunlight (photosensitivity) is a known potential effect associated with oral Metronidazole, it is not typically listed as an adverse reaction for the low-systemic-exposure vaginal tablet formulation.

Q: Can using Klion-D 100 disrupt the healthy bacteria in the vagina?

A: The medication is designed to eliminate susceptible pathogens, including protozoa and anaerobic bacteria. While regulatory documents do not explicitly state a disruption of the normal, healthy flora, the action against anaerobic bacteria may potentially alter the microbial balance within the vagina.

Q: Is Klion-D 100 used for treating all types of vaginitis?

A: Klion-D 100 is specifically indicated for the local management of vaginal infections caused by susceptible pathogens, including certain protozoa, anaerobic bacteria, and Candida species. It is not indicated for all types of vaginitis, which may have other causes not susceptible to its active components.

Official Storage and Disposal Requirements

Klion-D 100 vaginal tablets must be stored according to specific regulatory mandates to maintain the stability of the Metronidazole and Miconazole Nitrate components.

Storage Requirement	Official Regulatory Mandate
Temperature	Store at a temperature not exceeding 30 C (86 F) [Source: SmPC].
Environmental Protection	Store in the original package in order to protect from light [Source: SmPC].
Handling / Container	Keep the medication in the container it came in, tightly closed, and do not freeze [Source: FDA/NIH-aligned labeling].
Child Safety	Keep out of the reach and sight of children at all times [Source: Regulatory Labeling].

For disposal, unused or expired Klion-D 100 must be handled according to authorized local guidelines. The official instruction is to dispose of the unused product according to local requirements and not to discard it into wastewater or household trash unless directed by a healthcare authority [Source: Regulatory Guidance].